Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.45 |
| ▸ | TFPI2 | P48307 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | PPP5C | P53041 | 2/20 | 0.40 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880146 | 0.81 | TFPI2 (0.60) | PPM1BTFPI2KDM4EPPP5CPPP2CA | |
| SCHEMBL9880141 | 0.81 | TFPI2 (0.56) | PPM1BTFPI2KDM4EPPP5CPPP2CA | |
| SCHEMBL14135612 | 0.80 | TFPI2 (0.46) | PPM1BTFPI2PPP5CPPP2CANPY4R | |
| SCHEMBL9880144 | 0.78 | TFPI2 (0.45) | PPM1BTFPI2KDM4EPPP5CPPP2CA | |
| SCHEMBL21360341 | 0.78 | TFPI2 (0.45) | PPM1BTFPI2KDM4EPPP5CPPP2CA | |
| SCHEMBL9880153 | 0.78 | HSD11B1 (0.45) | PPM1BTFPI2KDM4EPPP5CPPP2CA | |
| SCHEMBL9880149 | 0.74 | RECQL (0.46) | TFPI2PPP5CPPP2CANPY4RMEN1 | |
| SCHEMBL13480836 | 0.72 | PPM1B (0.61) | PPM1BKDM4EALDH1A1L3MBTL1TP53 | |
| SCHEMBL6778458 | 0.72 | PPM1B (0.61) | PPM1BKDM4EALDH1A1L3MBTL1TP53 | |
| SCHEMBL1005051 | 0.72 | PPM1B (0.61) | PPM1BKDM4EALDH1A1L3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079917-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | PPM1B 3573/4885TFPI2 4858/4885KDM4E 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.